An assessment of statin safety by hepatologists

Am J Cardiol. 2006 Apr 17;97(8A):77C-81C. doi: 10.1016/j.amjcard.2005.12.014. Epub 2006 Feb 3.


The purpose of the Liver Expert Panel was to provide advice to the National Lipid Association's (NLA) Safety Task Force in response to specific questions concerning liver-associated risks of statin therapy. The panel was composed of academic hepatologists with clinical and research interests in nonalcoholic fatty liver disease, lipid metabolic disorders, and drug hepatotoxicity.

Publication types

  • Practice Guideline

MeSH terms

  • Alanine Transaminase / blood
  • Aspartate Aminotransferases / blood
  • Contraindications
  • Evidence-Based Medicine
  • Fatty Liver / drug therapy
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Liver / enzymology
  • Liver Failure / chemically induced*
  • Liver Function Tests
  • Liver Transplantation


  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Aspartate Aminotransferases
  • Alanine Transaminase